Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments - Segment Information (Details)

v3.22.1
Note 14 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Research and development expenses $ 1,169,254 $ 1,222,754  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,787,152 2,212,997  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 22,878 17,748  
Loss from operations [3] (2,979,284) (3,329,762)  
Other expense (4) [4] (7,961) 362,870  
Net loss (2,987,245) (2,966,892)  
Total assets, net of depreciation and amortization 3,602,125   $ 6,644,833
Capital expenditures 42,017 (0)  
Revenue from contract with customer 0 22,486  
Grant and other revenue 0 101,251  
Revenues, Total 0 123,737  
Research and development expenses 1,169,254 1,222,754  
UNITED STATES      
Total assets, net of depreciation and amortization 3,185,236 9,883,881  
Non-US [Member]      
Total assets, net of depreciation and amortization 416,889 193,194  
License [Member]      
Revenue from contract with customer 0 22,486  
Diagnostics Segment [Member]      
Research and development expenses 989,887 1,094,390  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 0 0  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 6,040 6,040  
Loss from operations [3] (995,927) (976,693)  
Other expense (4) [4] 0 0  
Net loss (995,927) (976,693)  
Capital expenditures 40,221 0  
Grant and other revenue   101,251  
Revenues, Total   123,737  
Research and development expenses 989,887 1,094,390  
Diagnostics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 150,920 160,669  
Diagnostics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization 393,753 193,194  
Diagnostics Segment [Member] | License [Member]      
Revenue from contract with customer   22,486  
Therapeutics Segment [Member]      
Research and development expenses 179,367 128,364  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 0 2,006  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 0 0  
Loss from operations [3] (179,367) (130,370)  
Other expense (4) [4] 0 0  
Net loss (179,367) (130,370)  
Capital expenditures 0 0  
Grant and other revenue   0  
Revenues, Total   0  
Research and development expenses 179,367 128,364  
Therapeutics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 0 0  
Therapeutics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization 0 0  
Therapeutics Segment [Member] | License [Member]      
Revenue from contract with customer   0  
Corporate Segment [Member]      
Research and development expenses 0 0  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,787,152 2,210,991  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 16,838 11,708  
Loss from operations [3] (1,803,990) (2,222,699)  
Other expense (4) [4] (7,961) 362,870  
Net loss (1,811,951) (1,859,829)  
Capital expenditures 1,796 0  
Grant and other revenue   0  
Revenues, Total   0  
Research and development expenses 0 0  
Corporate Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 3,034,316 9,723,212  
Corporate Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization $ 23,136 0  
Corporate Segment [Member] | License [Member]      
Revenue from contract with customer   $ 0  
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($22,878 and $17,748 for the three-month periods ended March 31, 2022 and 2021, respectively).
[3] Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of gain on extinguishment of debt, interest income and interest expense, which are not currently allocated to our individual reportable segments.